Alwin Capital Alwin Capital Alwin Capital

Alwin Capital

Identifying life science breakthroughs to address unmet clinical needs, we invest in translational medicine frontiers to capture China opportunities.

Positioning

Alwin Capital is a professional venture capital in China specializing in life science investments. Driven by theme-focused research in life science, Alwin Capital has developed investment strategies that capture outstanding opportunities for innovative diagnostic and therapeutic developments. We are committed to the long-term investment in life science with the pursuit of the excess investment return based on the scientific insights.

Founded in 2015, Alwin Capital was formed by former CICC senior executives, bringing in decades of experience in healthcare research and medical markets. Alwin Capital currently manage four venture funds with more than RMB 2 Billion in AUM, having invested in dozens of companies in life science and cultivated a bunch of leading companies in respective segments.

Portfolio

Over the past two decades, life science discoveries have been transformed into clinical applications and solutions, revealing a whole new horizon for healthcare industries. In the theme line based on gene sequencing, the industrial chain of molecular diagnosis has developed in an all-round way. In the theme line based on gene synthesis, drug research and development has entered the macromolecular platform from the small molecular platform, and then entered the living drug platform. In the theme line based on gene editing, new clinical technologies such as gene therapy have infiltrated the real clinical scenario. At the same time, life science, driven by artificial intelligence technology, has stepped a new development stage of digital life and precision medicine.

Under the current background of the development of life science and clinical medicine, adhering to the professional investment research in life science and the profound understanding of portfolio management, Alwin Capital has formed a systematic investment layout covering Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services and AI Applications.

  • alwin capital - Edigene

    Edigene

    The leader in gene editing new drug R&D in China with its product for β-thalassemia obtaining the first IND of gene therapy drugs in China

  • Reforgene

    The company with cutting-edge CRISPR technology in both in-vitro and in-vivo gene therapy product pipelines

  • NuiGene

    Innovative gene therapy company based on both AAV platform and CRISPR technology

  • immorna

    mRNA drug discovery company with systematic layout in vaccines of infectious diseases and I/O drugs

  • Neocura

    mRNA R&D company in China with pipelines of tumor neoantigen vaccines and other I/O drugs

  • Cell Therapy-Uni-CAR

    CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia

  • Xbiome

    Microbiome drug R&D company in China with global leading progress and advancement

  • Bliss Bio

    ADC drug R&D company with a seasoned management team

  • Kira Pharma

    Complement drug R&D company founded by globally prestigious scientist in the field of complement system

  • Adlai Nortye

    O/I drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.

  • Cancer Liquid Biopsy-Genecast

    The leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis

  • Mass Spectrometry Testing-Yingsheng Biology

    The key player in mass spectrometry testing market with a pipeline covering core products in China

  • Genetic Disease Testing-Chigene

    Genetic disease testing company with the largest database of genetic disease patients in China

  • Molecular Pathology Platform-Geneis:

    Multi-platform molecular pathology service provider to hospitals with comprehensive capabilities

  • Forensic DNA Testing-SuperBio

    The leader in forensic DNA testing with patented technologies and devices in China

  • DTC Gene Testing-23 MoFang

    The largest DTC gene testing company in China accounting for 40% market share

  • Synbio Tech

    High-throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies

  • Frasergen

    Scientific research service provider with advanced 3rd generation gene sequencing techniques

  • ONT Nanopore Sequencing-Qitan Tech

    ONT nanopore sequencer R&D company with the most advanced progress in China

  • Micro Droplet Platform-Sniper

    Digital PCR R&D company with innovative droplet generation technology platform

  • Edge Medical

    The leading surgical robot company in China with both single-hole and multi-hole endoscopic surgical robots in the pipeline

  • Rossum Robot

    A star-up company in the field of orthopedic robotics with its pelvic fracture reduction surgical robot holding global advancement

  • R&D

    The R&D company of high-value consumables for neural intervention with a complete product pipeline

  • FFR-CT AI Software-Keya Medical

    The leading AI image diagnosis company whose FFR-CT approved as the first AI Class III medical device by CFDA

  • Radiotherapy AI Software-Datu Medical

    AI imaging software company of radiotherapy with its planning software was first approved as the Class III medical device by CFDA

  • Click

    Digital manufacturer of invisible appliance based on automatic 3D printing technology

  • alwin capital - Edigene

    Edigene

    The leader in gene editing new drug R&D in China with its product for β-thalassemia obtaining the first IND of gene therapy drugs in China

  • Reforgene

    The company with cutting-edge CRISPR technology in both in-vitro and in-vivo gene therapy product pipelines

  • NuiGene

    Innovative gene therapy company based on both AAV platform and CRISPR technology

  • immorna

    mRNA drug discovery company with systematic layout in vaccines of infectious diseases and I/O drugs

  • Neocura

    mRNA R&D company in China with pipelines of tumor neoantigen vaccines and other I/O drugs

  • Cell Therapy-Uni-CAR

    CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia

  • Xbiome

    Microbiome drug R&D company in China with global leading progress and advancement

  • Bliss Bio

    ADC drug R&D company with a seasoned management team

  • Kira Pharma

    Complement drug R&D company founded by globally prestigious scientist in the field of complement system

  • Adlai Nortye

    O/I drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.

  • Cancer Liquid Biopsy-Genecast

    The leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis

  • Mass Spectrometry Testing-Yingsheng Biology

    The key player in mass spectrometry testing market with a pipeline covering core products in China

  • Genetic Disease Testing-Chigene

    Genetic disease testing company with the largest database of genetic disease patients in China

  • Molecular Pathology Platform-Geneis:

    Multi-platform molecular pathology service provider to hospitals with comprehensive capabilities

  • Forensic DNA Testing-SuperBio

    The leader in forensic DNA testing with patented technologies and devices in China

  • DTC Gene Testing-23 MoFang

    The largest DTC gene testing company in China accounting for 40% market share

  • Synbio Tech

    High-throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies

  • Frasergen

    Scientific research service provider with advanced 3rd generation gene sequencing techniques

  • ONT Nanopore Sequencing-Qitan Tech

    ONT nanopore sequencer R&D company with the most advanced progress in China

  • Micro Droplet Platform-Sniper

    Digital PCR R&D company with innovative droplet generation technology platform

  • Edge Medical

    The leading surgical robot company in China with both single-hole and multi-hole endoscopic surgical robots in the pipeline

  • Rossum Robot

    A star-up company in the field of orthopedic robotics with its pelvic fracture reduction surgical robot holding global advancement

  • R&D

    The R&D company of high-value consumables for neural intervention with a complete product pipeline

  • FFR-CT AI Software-Keya Medical

    The leading AI image diagnosis company whose FFR-CT approved as the first AI Class III medical device by CFDA

  • Radiotherapy AI Software-Datu Medical

    AI imaging software company of radiotherapy with its planning software was first approved as the Class III medical device by CFDA

  • Click

    Digital manufacturer of invisible appliance based on automatic 3D printing technology

Team

Alwin’s founding partners have been working together for nearly ten years, building a strong team culture and mutual trust over the course of their investment careers. They believe in science and the power of research. They all work in the front line to follow their beliefs and principles across their investment process. Strongly supported by a high-profile advisory board from the industry and capital market as well, Alwin is on track to explore and capture the investment opportunities in life science.

孙雅娜
Yana Sun Ph.D., CFA

Founding Partner
  • Medical Doctor from Peking Union Medical College
  • Managing Director with 13 years working experience at CICC
  • Was the top ranked healthcare equity analyst in China capital market
  • Was Head of Strategic Research and Head of Wealth Investment
  • Highly forward-looking judgment on industry and capital market

师惠京
Huijing Shi

M.S. from University of International Business and Economics
Founding Partner
  • M.S. from University of International Business and Economics
  • COO at CICC fund of hedge funds, managing over RMB 5 Billion across 10 funds
  • Strong capability in financial risk control and fund operation
  • Comprehensive network among top financial institutions in China

刘嘉运
Jiayun Liu

M.S. from Hong Kong University
Partner
  • MPH from Hong Kong University, B.S Med from Fudan University
  • Years of work experience in the field of medicine across primary and secondary markets
  • Accumulated rich research experience in the scientific theme lines with insights
  • Comprehensive and practical experience in investment execution

崔子剑
Zijian Cui

M.S. & B.S. from Tianjin University
Associate
  • M.S. & B.S. from Tianjin University
  • Years of working experience in M&A transaction advisory service
  • Skillful in the post-investment management with practical experience
  • Extensive experience in investment analysis and industry research

张连山
Lianshan Zhang Ph.D.

Senior Advisor
  • Senior Vice President, Chief Scientist at Hengrui Pharmaceutical
  • (the largest innovative pharmaceutical company in China)
  • Was Senior chemical director at Marcadia, USA
  • 10 years working experience in Eli Lilly
  • One of the leading people of new drug research and development in China

曾皓
Howard Zeng

Senior Advisor
  • Was Head of Corporate Development at BGI Genomics (the largest gene sequencing company in China)
  • 8 years working experience at Merrill Lynch Investment Banks
  • 4 years working experience in bioinformatics at Merck, US
  • Providing cross-border visions between US and China

邱劲
Jin Qiu Ph.D.

Senior Advisor
  • Ph.D. in Finance from McGill University
  • Chief Investment Officer at CICC
  • Was the Head of Equity Research at CICC
  • Holding extensive influence in China capital market with his senior background